View Single Post
Old 04-10-2020, 12:44   #414
Hugh
laeva recumbens anguis
Cable Forum Team
 
Hugh's Avatar
 
Join Date: Jun 2006
Age: 68
Services: Premiere Collection
Posts: 43,621
Hugh has a golden auraHugh has a golden auraHugh has a golden aura
Hugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden auraHugh has a golden aura
Re: U.S Election 2020

Quote:
Originally Posted by 1andrew1 View Post
The FT said there were actually two errors in the memo:

b) An incorrect name was used for the drug itself. The memo of 3rd October refers to it as a polyclonal antibody therapy whilst Regeneron's antibody therapy is monoclonal. Not an expert on the differences here eg if a cocktail is used, does it become "poly"?

b) Manufacturer's name, using the name Regeron instead of Regeneron. (Regeron focuses on reverse-aging biotechnology, especially on manufacturing human polypeptide growth factors for cosmetic applications including hair care).
A potential typo or genuine confusion with the other company.
Quote:
Originally Posted by pip08456 View Post
Polyclonal is a mixture of T3 antibody cloned genes. Monoclonal uses the same cloned T3 antibody gene.
Quote:
Originally Posted by 1andrew1 View Post
Thanks, an important difference then.
Quote:
About REGN-COV2

REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's VelocImmuneŽ mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science. Preclinical studies have shown that REGN-COV2 reduced the amount of virus and associated damage in the lungs of non-human primates.
https://investor.regeneron.com/news-...ral-levels-and
__________________
Thank you for calling the Abyss.
If you have called to scream, please press 1 to be transferred to the Void, or press 2 to begin your stare.

If my post is in bold and this colour, it's a Moderator Request.

Last edited by Hugh; 04-10-2020 at 12:47.
Hugh is offline